Guggenheim Capital LLC Crispr Therapeutics Ag Transaction History

Guggenheim Capital LLC

$10.6 Billion
Q1 2025

A detailed history of Guggenheim Capital LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Guggenheim Capital LLC holds 96,266 shares of CRSP stock, worth $3.49 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

96,266

Previous 87,201 10.4%

Holding current value

$3.49 Million

Previous $3.43 Million 4.57%

% of portfolio

0.03%

Previous 0.03%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$34.03 - $53.02 $308,481 - $480,626	9,065 Added 10.4%	96,266 $3.28 Million
Q4 2024 Feb 13, 2025	SELL	$38.65 - $55.15 $25,895 - $36,950	-670 Reduced 0.76%	87,201 $3.43 Million
Q3 2024 Nov 13, 2024	BUY	$44.62 - $62.75 $1.54 Million - $2.17 Million	34,518 Added 64.7%	87,871 $4.13 Million
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $173,210 - $230,789	3,385 Added 6.77%	53,353 $2.88 Million
Q1 2024 May 14, 2024	BUY	$60.67 - $89.12 $857,145 - $1.26 Million	14,128 Added 39.42%	49,968 $3.41 Million
Q4 2023 Feb 14, 2024	SELL	$38.62 - $72.18 $552,729 - $1.03 Million	-14,312 Reduced 28.54%	35,840 $2.24 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $876,617 - $1.14 Million	-19,313 Reduced 27.8%	50,152 $2.28 Million
Q2 2023 Aug 11, 2023	SELL	$43.47 - $67.77 $241,258 - $376,123	-5,550 Reduced 7.4%	69,465 $3.9 Million
Q1 2023 May 10, 2023	SELL	$41.0 - $56.12 $288,517 - $394,916	-7,037 Reduced 8.58%	75,015 $3.39 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $172,553 - $289,145	4,403 Added 5.67%	82,052 $3.34 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $256,375 - $351,540	4,196 Added 5.71%	77,649 $5.07 Million
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $99,429 - $169,809	-2,300 Reduced 3.04%	73,453 $4.46 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $541,793 - $807,138	-10,186 Reduced 11.85%	75,753 $4.76 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $1.44 Million - $2.29 Million	20,566 Added 31.46%	85,939 $6.51 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $3.71 Million - $5.27 Million	33,651 Added 106.08%	65,373 $7.32 Million
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $35,495 - $56,985	352 Added 1.12%	31,722 $5.14 Million
Q1 2021 May 13, 2021	BUY	$110.72 - $210.04 $1.39 Million - $2.63 Million	12,539 Added 66.59%	31,370 $3.82 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $1.5 Million - $3.26 Million	18,831 New	18,831 $2.88 Million

Others Institutions Holding CRSP

# of Institutions

479

Shares Held

64.2M

Call Options Held

2.15M

Put Options Held

1.92M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $2.83B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Crispr Therapeutics Ag Transaction History